1. Discovery of novel small molecules targeting hepatitis B virus core protein from marine natural products with HiBiT-based high-throughput screening.
- Author
-
Huang, Chao, Jin, Yang, Fu, Panpan, Hu, Kongying, Wang, Mengxue, Zai, Wenjing, Hua, Ting, Song, Xinluo, Ye, Jianyu, Zhang, Yiqing, Luo, Gan, Wang, Haiyu, Liu, Jiangxia, Chen, Jieliang, Li, Xuwen, and Yuan, Zhenghong
- Subjects
MARINE natural products ,HEPATITIS B virus ,LEAD compounds ,HIGH throughput screening (Drug development) ,SMALL molecules - Abstract
Due to the limitations of current anti-HBV therapies, the HBV core (HBc or HBcAg) protein assembly modulators (CpAMs) are believed to be potential anti-HBV agents. Therefore, discovering safe and efficient CpAMs is of great value. In this study, we established a HiBiT-based high-throughput screening system targeting HBc and screened novel CpAMs from an in-house marine chemicals library. A novel lead compound 8a , a derivative of the marine natural product naamidine J, has been successfully screened for potential anti-HBV activity. Bioactivity-driven synthesis was then conducted, and the structure‒activity relationship was analyzed, resulting in the discovery of the most effective compound 11a (IC 50 = 0.24 μmol/L). Furthermore, 11a was found to significantly inhibit HBV replication in multiple cell models and exhibit a synergistic effect with tenofovir disoproxil fumarate (TDF) and IFNa2 in vitro for anti-HBV activity. Treatment with 11a in a hydrodynamic-injection mouse model demonstrated significant anti-HBV activity without apparent hepatotoxicity. These findings suggest that the naamidine J derivative 11a could be used as the HBV core protein assembly modulator to develop safe and effective anti-HBV therapies. A new CpAM was screened by HTS system (Huh7-LTCH). Under the bioactivity-driven synthesis, we designed the best compound 11a , which can effectively inhibit HBV DNA in vitro and in vivo. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF